Humana Inc. $HUM Shares Acquired by Allstate Corp

Key Points

• Allstate Corp increased its stake in Humana Inc. by 25.3% in Q1, bringing its total holdings to 4,469 shares valued at approximately $1.18 million.
• Humana recently reported a net margin of 1.28% with a revenue of $32.39 billion, exceeding analysts' estimates.
• The company announced a quarterly dividend of $0.885 per share, which translates to an annualized dividend of $3.54, reflecting a yield of 1.2%.

Allstate Corp lifted its stake in shares of Humana Inc. (NYSE:HUM - Free Report) by 25.3% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,469 shares of the insurance provider's stock after buying an additional 902 shares during the quarter. Allstate Corp's holdings in Humana were worth $1,182,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Cary Street Partners Investment Advisory LLC lifted its position in shares of Humana by 63.9% during the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider's stock worth $31,000 after buying an additional 46 shares during the last quarter. Riverview Trust Co purchased a new stake in shares of Humana during the 1st quarter worth approximately $34,000. Garde Capital Inc. purchased a new stake in shares of Humana during the 1st quarter worth approximately $36,000. Zions Bancorporation National Association UT purchased a new stake in shares of Humana during the 1st quarter worth approximately $37,000. Finally, Whipplewood Advisors LLC lifted its position in shares of Humana by 639.1% during the 1st quarter. Whipplewood Advisors LLC now owns 170 shares of the insurance provider's stock worth $45,000 after buying an additional 147 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company's stock.

Humana Stock Performance

HUM traded down $1.57 during trading on Wednesday, hitting $297.30. The stock had a trading volume of 859,256 shares, compared to its average volume of 1,712,624. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.95 and a current ratio of 1.95. The firm has a market capitalization of $35.76 billion, a P/E ratio of 22.82, a PEG ratio of 1.75 and a beta of 0.44. The company's 50-day moving average price is $250.98 and its 200 day moving average price is $253.78. Humana Inc. has a twelve month low of $206.87 and a twelve month high of $382.72.

Humana (NYSE:HUM - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.32 by ($0.05). The firm had revenue of $32.39 billion during the quarter, compared to analyst estimates of $31.85 billion. Humana had a net margin of 1.28% and a return on equity of 13.67%. The business's quarterly revenue was up 9.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $6.96 earnings per share. Humana has set its FY 2025 guidance at 17.000- EPS. On average, equities research analysts forecast that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be paid a $0.885 dividend. This represents a $3.54 annualized dividend and a yield of 1.2%. The ex-dividend date of this dividend is Friday, September 26th. Humana's payout ratio is currently 27.17%.

Wall Street Analyst Weigh In

HUM has been the subject of several recent analyst reports. Barclays set a $275.00 price objective on shares of Humana and gave the stock an "equal weight" rating in a research report on Thursday, July 31st. Wall Street Zen downgraded shares of Humana from a "buy" rating to a "hold" rating in a research report on Saturday, August 2nd. Robert W. Baird reduced their price objective on shares of Humana from $300.00 to $297.00 and set a "neutral" rating for the company in a research report on Friday, July 25th. Cantor Fitzgerald reiterated a "neutral" rating and issued a $290.00 price target on shares of Humana in a research report on Thursday, May 1st. Finally, Wells Fargo & Company reduced their price target on shares of Humana from $348.00 to $344.00 and set an "overweight" rating for the company in a research report on Thursday, August 14th. Seven analysts have rated the stock with a Buy rating and sixteen have given a Hold rating to the company. According to MarketBeat, Humana currently has a consensus rating of "Hold" and a consensus price target of $283.29.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.